CA2560843A1 - Novel method of neuroprotection by pharmacological inhibition of amp-activated protein kinase - Google Patents

Novel method of neuroprotection by pharmacological inhibition of amp-activated protein kinase Download PDF

Info

Publication number
CA2560843A1
CA2560843A1 CA002560843A CA2560843A CA2560843A1 CA 2560843 A1 CA2560843 A1 CA 2560843A1 CA 002560843 A CA002560843 A CA 002560843A CA 2560843 A CA2560843 A CA 2560843A CA 2560843 A1 CA2560843 A1 CA 2560843A1
Authority
CA
Canada
Prior art keywords
ampk
stroke
ischemic
pampk
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002560843A
Other languages
English (en)
French (fr)
Inventor
Louise D. McCullough
Jill Mcfadden
Gabriele V. Ronnett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Johns Hopkins University
Fasgen LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University, Fasgen LLC filed Critical Johns Hopkins University
Publication of CA2560843A1 publication Critical patent/CA2560843A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA002560843A 2004-03-24 2005-03-23 Novel method of neuroprotection by pharmacological inhibition of amp-activated protein kinase Abandoned CA2560843A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55600004P 2004-03-24 2004-03-24
US60/556,000 2004-03-24
PCT/US2005/009797 WO2005092068A2 (en) 2004-03-24 2005-03-23 Novel method of neuroprotection by pharmacological inhibition of amp-activated protein kinase

Publications (1)

Publication Number Publication Date
CA2560843A1 true CA2560843A1 (en) 2005-10-06

Family

ID=35056772

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002560843A Abandoned CA2560843A1 (en) 2004-03-24 2005-03-23 Novel method of neuroprotection by pharmacological inhibition of amp-activated protein kinase

Country Status (11)

Country Link
US (1) US8293791B2 (https=)
EP (1) EP1734973A4 (https=)
JP (1) JP2008504228A (https=)
KR (2) KR20070085093A (https=)
CN (1) CN101132802A (https=)
AU (1) AU2005226731A1 (https=)
BR (1) BRPI0509085A (https=)
CA (1) CA2560843A1 (https=)
IL (1) IL178242A0 (https=)
MX (1) MXPA06010916A (https=)
WO (1) WO2005092068A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06010916A (es) 2004-03-24 2007-07-25 Fasgen Llc Novedoso metodo de proteccion neurologica mediante inhibicion farmacologica de proteina quinasa activada por amp.
KR101152607B1 (ko) 2005-12-20 2012-06-05 에스케이케미칼주식회사 ６-[４-(２-피페리딘-1-일-에톡시)-페닐]-３-피리딘-４-일-피라졸로[１,５-ａ]피리미딘의 제조방법
KR101787116B1 (ko) 2009-01-28 2017-10-18 케러 테라퓨틱스, 인코포레이티드 바이시클릭 피라졸로-헤테로사이클
US7741350B1 (en) * 2009-01-28 2010-06-22 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
EP2978307B1 (en) 2013-03-28 2018-12-26 The Trustees of Columbia University in the City of New York Reperfusion with omega-3 glycerides promotes donor organ protection for transplantation
KR101532211B1 (ko) * 2014-04-30 2015-06-30 세종대학교산학협력단 Ampk 억제기능에 기반한 뇌졸중 치료용 약학적 조성물 및 방법
CN119868551B (zh) * 2024-11-28 2026-04-14 四川大学华西医院 F-box蛋白48的抑制剂的新用途和治疗缺血性脑血管病的药物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9602080D0 (en) * 1996-02-02 1996-04-03 Pfizer Ltd Pharmaceutical compounds
US5981575A (en) * 1996-11-15 1999-11-09 Johns Hopkins University, The Inhibition of fatty acid synthase as a means to reduce adipocyte mass
CO5180581A1 (es) 1999-09-30 2002-07-30 Pfizer Prod Inc Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia
IL147696A0 (en) * 2001-01-25 2002-08-14 Pfizer Prod Inc Combination therapy
US6423705B1 (en) * 2001-01-25 2002-07-23 Pfizer Inc. Combination therapy
MXPA06010916A (es) 2004-03-24 2007-07-25 Fasgen Llc Novedoso metodo de proteccion neurologica mediante inhibicion farmacologica de proteina quinasa activada por amp.

Also Published As

Publication number Publication date
KR20070085093A (ko) 2007-08-27
US20090137665A1 (en) 2009-05-28
MXPA06010916A (es) 2007-07-25
EP1734973A4 (en) 2010-08-04
JP2008504228A (ja) 2008-02-14
EP1734973A2 (en) 2006-12-27
AU2005226731A1 (en) 2005-10-06
WO2005092068A2 (en) 2005-10-06
KR101283416B1 (ko) 2013-07-08
BRPI0509085A (pt) 2007-08-21
IL178242A0 (en) 2007-03-08
US8293791B2 (en) 2012-10-23
CN101132802A (zh) 2008-02-27
KR20120078756A (ko) 2012-07-10
WO2005092068A3 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
McCullough et al. Pharmacological inhibition of AMP-activated protein kinase provides neuroprotection in stroke
Titus et al. Mitophagy for cardioprotection
Zepeda et al. Drp1 loss-of-function reduces cardiomyocyte oxygen dependence protecting the heart from ischemia-reperfusion injury
Hurtado et al. Neuroprotection afforded by prior citicoline administration in experimental brain ischemia: effects on glutamate transport
Eskew et al. Cellular protection mechanisms against extracellular heme: heme-hemopexin, but not free heme, activates the N-terminal c-Jun kinase
Kuwana et al. The phosphoinositide-3 kinase γ–Akt pathway mediates renal tubular injury in cisplatin nephrotoxicity
Zhong et al. Protein S protects neurons from excitotoxic injury by activating the TAM receptor Tyro3–Phosphatidylinositol 3-Kinase–Akt pathway through its sex hormone-binding globulin-like region
NO332038B1 (no) Beskyttelse, gjenoppbygging og styrking av erytropoietinresponsive celler, vev og organer.
Bright et al. δPKC mediates microcerebrovascular dysfunction in acute ischemia and in chronic hypertensive stress in vivo
JP7594441B2 (ja) 凍結保存用組成物およびその使用方法
Takada et al. Cytoprotective effect of sodium orthovanadate on ischemia/reperfusion-induced injury in the rat heart involves Akt activation and inhibition of fodrin breakdown and apoptosis
JP4387101B2 (ja) 糖尿病性網膜症の予防または処置のための網膜細胞アポトーシス抑制剤の使用
JP2001526658A (ja) 虚血の治療および／または予防を行う際の医薬組成物の使用
Watanabe et al. Restriction of food intake prevents postinfarction heart failure by enhancing autophagy in the surviving cardiomyocytes
Hayashi et al. Beneficial effects of MET-88, a γ-butyrobetaine hydroxylase inhibitor in rats with heart failure following myocardial infarction
Kelleher et al. Energy metabolism in hypoxic astrocytes: protective mechanism of fructose-1, 6-bisphosphate
US8293791B2 (en) Method of neuroprotection by pharmacological inhibition of AMP-activated protein kinase
Jia et al. Nrf2 participates in the protective effect of exogenous mitochondria against mitochondrial dysfunction in myocardial ischaemic and hypoxic injury
ES2992725T3 (en) Glycolic acid and/or d-lactic acid for the treatment of neurodegenerative diseases
Wang et al. Salusins protect myocardium against ischemic injury by alleviating endoplasmic reticulum stress
PL209912B1 (pl) Zastosowanie inhibitora kinazy tyrozynowej w medycynie
HK1118217A (en) Novel method of neuroprotection by pharmacological inhibition of amp-activated protein kinase
KR20220015428A (ko) 단백질 클로토(Klotho)의 생산을 활성화할 수 있는 시트레이트 및 카르니틴을 포함하는 조성물
Schachter et al. Regional differentiation in the rat aorta: effects of cyclooxygenase inhibitors
US20230125482A1 (en) Protein kinase c modulators

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued